healthspan Tag

08 Jul

Posted at 11:38h in Aging, Telemedicine

Supplements, Peptide & Hormone Therapy Notice: The treatments, supplements, peptides, and hormone optimization therapies referenced in this article are not FDA monitored or approved for all uses described. These therapies should only be undertaken under the supervision of a qualified, licensed healthcare provider following a thorough clinical assessment. Dosing is variable and individualized; self-administration without medical oversight is not recommended. These therapies may interfere with existing medications and may be contraindicated in individuals with certain health conditions, including cardiovascular disease, hormone-sensitive cancers, liver conditions, or clotting disorders. Do not use hormone therapies or peptide compounds if you are pregnant, nursing, or may become pregnant. Keep all therapeutic compounds out of reach of children. Always consult your physician before beginning, modifying, or discontinuing any hormone, peptide, or supplement protocol.

The pursuit of a longer life has dominated medical science for decades, but the conversation is rapidly shifting toward the quality of those additional years. Today, healthcare professionals are focusing on the distinction between lifespan and healthspan. As researchers evaluating proactive healthcare and telehealth innovations frequently explore, modern medicine is transitioning away from reactive symptom management. Instead, there is a strong global emphasis on early lifestyle interventions and increasing patient access to preventive medical assessments via virtual care.

This evolution in care delivery is also reshaping how aging populations engage with technology, a shift explored in detail in this overview of tech-smart aging for home, help and health.

The Impact of Precision Telehealth on Preventive Care and Healthy Ageing

12 Feb

Posted at 16:45h in Aging, Author Interviews, Genetic Research
MedicalResearch.com Interview with: [caption id="attachment_47448" align="alignleft" width="200"]Yurii Aulchenko Co-founder and Chief Scientist of PolyOmica Yurii Aulchenko[/caption] Yurii Aulchenko Co-founder and Chief Scientist of PolyOmica PolyOmica is a research & development company providing services and tools for quantitative genetics and functional genomics. [caption id="attachment_47449" align="alignleft" width="150"]Peter Fedichev Founder and Chief Science Officer of Gero Peter Fedichev[/caption] Peter Fedichev Founder and Chief Science Officer of Gero Gero is a data-driven longevity company developing innovative therapies that will strongly extend the healthy period of life also known as healthspan MedicalResearch.com: What is the background for this study? What are the main findings? Peter Fedichev, Gero: Age is the most important risk factor behind age-related diseases and death. Lifespan has increased quite dramatically over the last 150-200 years mostly due to the eradication of early-life mortality. What we find, however, is that the healthspan, understood as the chronic diseases-free period, is also on the rise, but not so much. It appears that lifespan is modifiable by interventions, at least in lab animals. It is therefore crucial to understand if the biology behind human healthspan. Is it the same as that of lifespan? What are the molecular pathways and genetic factors controlling the healthspan? At the end, we would like to develop interventions that extend not only lifespan, but also the healthspan. Everyone wants to stay healthy! Yurii Aulchenko, PolyOmica: We studied the incidence of the most prevalent age-related diseases in the large UK Biobank, one of the best repositories of biologically and medically relevant data from a very large cohort of aging individuals. We observed that the incidence (the chances of) all the major diseases increased exponentially with age. The diseases risk doubling time was about eight years, same as the mortality doubling time from the Gompertz mortality law, discovered as early as in 1825 and used in life insurance ever since. The similar patterns of age-dependent risk acceleration suggest a major common driver behind the diseases, that is most plausibly aging itself. Peter Fedichev, Gero: The incidence of the diseases could, therefore, be used as a biomarker of aging process. We used the age at the onset of the first age-related disease (the end of healthspan) as the target for a genome-wide association study (GWAS) and identified as many as 12 genetic loci associated with human healthspan.